Woodline Partners’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
Other funds holding DNTH
FFM
APM
OCA
Woodline Partners's DNTH Position: Q2 2026 in Review
Woodline Partners increased its Dianthus Therapeutics (DNTH) stake by 15% in Q2 2026, buying an estimated $5.86M and bringing the position to 500,548 shares worth $48.8M. The position accounts for 0.15% of the portfolio, ranked #178.
Woodline Partners first reported a position in DNTH in Q3 2021 and has held it in 14 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.
- Woodline Partners held 500,548 shares of Dianthus Therapeutics worth $48.8M as of Q2 2026.
- Woodline Partners bought 67,091 Dianthus Therapeutics shares in Q2 2026, an estimated $5.86M.
- Dianthus Therapeutics made up 0.15% of Woodline Partners's portfolio in Q2 2026, its #178 holding.
- Woodline Partners first reported a position in Dianthus Therapeutics in Q3 2021 and has held it in 14 quarters since.
- 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.
Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.